



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Catalano, et al.

Serial No.: 10/501,636 Group Art Unit: 1646

Filing Date: July 15, 2004 Examiner:

For: CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed
- ☐ Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))
- ☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☐ The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: 8/30/05

Allyson K. Jacobs
Allyson K. Jacobs

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,

Kathryn L. Coulter

Kathryn L. Coulter
Agent for Appliant
Registration No. 45,889

Date: 8/21/2005

GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1467
Facsimile: (919) 483-7988

FORM PTO-1449
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
ATTORNEY DOCKET
NO.
PU4601 USW
SERIAL NO.
10/501,636
APPLICANT
Catalano et al.
FILING DATE
7/15/04
GROUP
U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	6,235,929	5/22/01	Powers et al.			
	2	5,501,969	3/26/96	Hastings et al.			
	3	5,650,508	7/22/97	Powers			
	4	5,610,297	3/11/97	Powers			
	5	5,444,042	8/22/95	Bartus et al.			
	6	5,514,694	5/7/96	Zhaozhao et al.			
	7	5,670,479	9/23/97	Abelman et al.			

Continue on page ____

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	14	96/16079	5/30/96	PCT			
	15	97/16177	5/9/97	PCT			
	16	92/12140	7/23/92	PCT			
	17	1 008 592	6/14/00	EP			
	18	520 427	12/30/92	EP			
	19	92/11850	7/23/92	PCT			
	20	535 928	4/7/93	EP			
	21	525 420	2/3/93	EP			
	22	93/24634	12/9/93	PCT			
	23	94/21673	9/29/94	PCT			

Continue on page ____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)


	82	Tezuka et al., "Molecular Cloning of a Possible Cystein Proteinase Predominantly Expressed in Osteoclasts," <u>J. Biol. Chem.</u> , 1994, Vol. 269, pp.1106 - 1109.
	83	Inaoka et al., "Molecular Cloning of Human cDNA for Cathepsin K: Novel Cysteine Proteinase Predominately Expressed in Bone," <u>Biochem. Biophys. Res. Commun.</u> , 1995, Vol. 206, p. 89.
	84	Shi, et al., "Molecular cloning of human cathepsin I, a novel endoproteinase asn homologue of rabbit OC2," <u>FEBS Letters</u> , 1995, Vol. 357, p. 129


Continue on page ____


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PU4601 USW		SERIAL NO. 10/501,636	
				APPLICANT Catalano et al.			
				FILING DATE 7/15/02		GROUP	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	8	5,763,576	6/9/98	Powers			
	9	5,861,298	1/19/99	Adams et al.			
	10	5,948,886	9/7/99	Peet et al.			
	11	6,143,931	11/7/00	Baldino et al.			
	12	6,448,254	9/10/02	Lubisch et al.			
Continue on page ____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	24	603 873	6/29/94	EP			
	25	06192199	7/12/94	JP			
	26	94/00095	1/6/94	PCT			
	27	95/00535	1/5/95	PCT			
	28	611 756	8/24/94	EP			
	29	94/08941	4/28/94	PCT			
	30	07115985	5/9/95	JP			
	31	96/32408	10/17/96	PCT			
	32	96/10014	4/4/96	PCT			
	33	96/40647	12/19/96	PCT			
	34	812 916	12/17/97	EP			
	35	97/16433	5/9/97	PCT			
	36	97/49668	12/31/97	PCT			
	37	97/47642	12/18/97	PCT			
	38	98/46559	10/22/98	PCT			
	39	98/50342	11/12/98	PCT			
	40	9846582	10/22/98	PCT			
	41	98/48799	11/5/98	PCT			
	42	98/50534	11/12/98	PCT			
	43	98/05336	2/12/98	PCT			
	44	98/48190	10/29/98	PCT			
Continue on page ____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
Continue on page ____							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PU4601 USW		SERIAL NO. 10/501,636	
				APPLICANT Catalano et al.			
				FILING DATE 7/15/04		GROUP	
U.S. PATENT DOCUMENTS							
Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate	
	13	6,436,925	8/20/02	Lubisch et al.			
Continue on page ____							
FOREIGN PATENT DOCUMENTS							
	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No	
	45	98/08802	3/5/98	PCT			
	46	99/24460	5/20/99	PCT			
	47	99/59526	11/25/99	PCT			
	48	99/17790	4/15/99	PCT			
	49	99/17778	4/15/99	PCT			
	50	99/17775	4/15/99	PCT			
	51	99/11637	3/11/99	PCT			
	52	99/64399	12/16/99	PCT			
	53	99/66925	12/29/99	PCT			
	54	99/59570	11/25/99	PCT			
	55	99/54305	10/28/99	PCT			
	56	99/54310	10/28/99	PCT			
	57	99/54320	10/28/99	PCT			
	58	99/61423	12/2/99	PCT			
	59	11246436	9/14/99	JP			
	60	11263783	7/12/94	JP			
	61	99/11640	3/11/99	PCT			
	62	99/54317	10/28/99	PCT			
Continue on page ____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
Continue on page ____							
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PU4601 USW		SERIAL NO. 10/501,636	
				APPLICANT Catalano et al.			
				FILING DATE 7/15/04		GROUP	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continue on page ____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	63	99/53039	10/21/99	PCT			
	64	99/37666	7/21/99	PCT			
	65	11228526	8/24/99	JP			
	66	00/01666	1/13/00	PCT			
	67	00/18725	4/6/00	PCT			
	68	00/18358	4/6/00	PCT			
	69	00/16767	3/30/00	PCT			
	70	00/24704	5/4/00	PCT			
	71	00/29408	5/25/00	PCT			
	72	00/51998	9/8/00	PCT			
	73	00/59881	10/12/00	PCT			
	74	00/58296	10/5/00	PCT			
	75	00/54769	9/21/00	PCT			
	76	00/55124	9/21/00	PCT			
	77	00/55144	9/21/00	PCT			
	78	01/09169	2/8/01	PCT			
	79	2001011037		JP			
	80	200281640-A		JP			
	81	00/78794	12/28/00	PCT			
Continue on page ____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
Continue on page ____							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							